Could Gilead Sciences Have an HIV Cure Waiting in the Wings?

Most of the buzz over Gilead Sciences (NASDAQ:GILD) in recent months has centered on its antiviral drug remdesivir. That's understandable, considering that the drug is currently the most promising therapy targeting COVID-19.

Gilead has also been in headlines over the past week after reports surfaced that big pharmaceutical company AstraZeneca was interested in acquiring the biotech. The possibility of a deal, though, seems to have evaporated now.